Integra Lifesciences Holdings (IART) Stock Value Declined While Champlain Investment Partners LLC Lifted Position

October 13, 2018 - By Peter Kolinski

Investors sentiment increased to 1.24 in Q2 2018. Its up 0.32, from 0.92 in 2018Q1. It improved, as 23 investors sold IART shares while 70 reduced holdings. 48 funds opened positions while 67 raised stakes. 70.93 million shares or 2.45% more from 69.24 million shares in 2018Q1 were reported. 68,101 were accumulated by First Trust Advisors Lp. Global X Mngmt Limited Liability holds 1,039 shares or 0% of its portfolio. Prudential Financial has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Gam Ag has 0.07% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 194 are held by Parkside Fincl Bancorporation. Chase Inv Counsel reported 8,525 shares. Blackrock holds 6.41 million shares or 0.02% of its portfolio. Invesco Ltd stated it has 1.13M shares or 0.02% of all its holdings. Tiaa Cref Ltd Llc stated it has 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Laurion Mgmt Ltd Partnership stated it has 22,829 shares. Plante Moran Advsr Ltd Liability Co invested 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Commercial Bank Of Montreal Can accumulated 16,018 shares. Castleark Management Llc has invested 0.56% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). New York State Teachers Retirement Sys has 76,058 shares. Eulav Asset, New York-based fund reported 15,900 shares.

Champlain Investment Partners Llc increased its stake in Integra Lifesciences Holdings (IART) by 2.68% based on its latest 2018Q2 regulatory filing with the SEC. Champlain Investment Partners Llc bought 133,875 shares as the company’s stock declined 1.75% while stock markets rallied. The institutional investor held 5.13 million shares of the laboratory analytical instruments company at the end of 2018Q2, valued at $330.52 million, up from 5.00 million at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Integra Lifesciences Holdings for a number of months, seems to be bullish on the $5.28B market cap company. The stock increased 2.14% or $1.3 during the last trading session, reaching $61.96. About 765,455 shares traded or 8.86% up from the average. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 21.16% since October 13, 2017 and is uptrending. It has outperformed by 5.54% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04 billion and $10.33B US Long portfolio, decreased its stake in Omnicell Inc. (NASDAQ:OMCL) by 184,965 shares to 1.32 million shares, valued at $69.26M in 2018Q2, according to the filing. It also reduced its holding in Wolverine World Wide Inc. (NYSE:WWW) by 615,975 shares in the quarter, leaving it with 1.98M shares, and cut its stake in Akamai Technologies Inc. (NASDAQ:AKAM).

More news for Integra LifeSciences Holdings Corporation (NASDAQ:IART) were recently published by: Nasdaq.com, which released: “New Research Coverage Highlights Harley-Davidson, Ritchie Bros. Auctioneers, Devon Energy, Dunkin’ Brands Group …” on October 04, 2018. Globenewswire.com‘s article titled: “Integra LifeSciences to participate in the Cantor Global Healthcare Conference” and published on September 19, 2018 is yet another important article.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Among 7 analysts covering Integra Lifesciences (NASDAQ:IART), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Integra Lifesciences had 8 analyst reports since April 25, 2018 according to SRatingsIntel. The firm has “Neutral” rating by JP Morgan given on Thursday, April 26. BTIG Research upgraded the stock to “Buy” rating in Thursday, July 26 report. The stock has “Underperform” rating by Bank of America on Tuesday, August 7. Citigroup downgraded the shares of IART in report on Monday, July 2 to “Neutral” rating. Cantor Fitzgerald maintained it with “Hold” rating and $5200 target in Wednesday, April 25 report. The rating was maintained by Morgan Stanley on Thursday, October 11 with “Equal-Weight”. JP Morgan maintained the shares of IART in report on Tuesday, May 22 with “Neutral” rating. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Buy” rating by Jefferies on Wednesday, April 25.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>